Scalp Cooling Reduces Risk of Chemotherapy-Induced Alopecia

Share this content:
Hair loss is a common side effect related to chemotherapy that affects quality of life.
Hair loss is a common side effect related to chemotherapy that affects quality of life.

Among patients with breast cancer receiving neoadjuvant or adjuvant chemotherapy, those who underwent scalp cooling were significantly less likely to experience chemotherapy-induced hair loss than those who did not receive scalp cooling, a study published in JAMA has shown.1

Although scalp cooling devices have been used to prevent alopecia caused by chemotherapy, its efficacy has not been established in a randomized clinical trial. Therefore, researchers sought to evaluate the efficacy and safety of scalp cooling compared with no treatment in women with breast cancer undergoing chemotherapy.

For the multicenter study (ClinicalTrials.gov Identifier: NCT01986140), investigators enrolled 182 patients receiving neoadjuvant or adjuvant chemotherapy with a taxane, anthracycline, or both, at 7 sites in the United States and randomly assigned them 2:1 to undergo scalp cooling with Orbis Paxman Hair Loss Prevention System or control. Their average age was approximately 53 years and 36% and 64% received anthracycline-based and taxane-based chemotherapy, respectively.

The interim analysis showed that 50.5% (95% CI, 40.7-60.4) of the 95 evaluable women in the scalp cooling experienced successful hair preservation, defined as no hair loss or less than 50% hair loss without requiring a wig at the end of 4 cycles of chemotherapy, compared with 0% (95% CI, 0-7.6). The investigators stopped the trial early due to scalp cooling being superior to no treatment (P =.0061).

Notably, there were no statistically significant differences in changes in quality of life from baseline to cycle 4 of chemotherapy between the 2 groups. 

Investigators observed 54 adverse events in the cooling group. All were grade 1 to 2 toxicities. There were no serious adverse device events.

The findings suggest that scalp cooling is more likely to prevent chemotherapy-induced alopecia in patients with breast cancer than no treatment; however, further research is necessary to evaluate its long-term efficacy and safety.

Reference

1. Nangia J, Wang T, Osborne C, et al. Effect of a scalp cooling device on alopecia in women undergoing chemotherapy for breast cancer. JAMA. 2017;317(6):596-605.

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs